Nitrogen Heterocyclic Compound for Marker-Selective Tumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tumors lack precision, often leading to improper treatment due to tumor heterogeneity, delaying effective therapy and causing toxic side effects.
Innovation Solution
A nitrogen-containing heterocyclic compound designed to target tumors with specific molecular markers, such as low NNMT gene expression and high UHRF1 and DNA methylation levels, providing precise treatment options.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If the same treatment method or medication is used for all tumors based on source or pathological characteristic, then treatment simplicity is maintained, but treatment precision deteriorates leading to improper treatment
Solution Approach 1:
The patent develops a compound with selective affinity for specific tumor molecular markers (NNMT, UHRF1, DNA methylase) rather than uniform action on all tumors. The compound's chemical structure is designed to interact specifically with tumors exhibiting particular molecular characteristics, enabling differentiated treatment based on local molecular quality of each tumor type.
Solution Approach 2:
The invention changes the parameter of treatment specificity by targeting molecular-level characteristics (gene expression levels, protein expression, methylation status) rather than traditional macroscopic tumor classification. This parameter shift from gross morphology to molecular markers enables precise identification and treatment of specific tumor subtypes.
2Reliability
If high dosage of drug is administered to ensure treatment effect, then treatment efficacy is improved, but toxic side effects increase
Solution Approach 1:
The compound exhibits selective toxicity through its specific molecular target recognition. By designing the drug to bind preferentially to tumors with specific molecular markers (low NNMT expression, high UHRF1 expression, high DNA methylation), the treatment achieves localized action on target tumors while sparing normal tissues and non-target tumors, thereby reducing systemic toxic side effects.
Solution Approach 2:
The patent introduces molecular markers (NNMT, UHRF1, DNA methylase) as intermediaries that mediate between the drug and tumor cells. The compound acts through these specific molecular pathways, allowing selective engagement with target tumors via their unique molecular profile, which serves as an intermediary mechanism for precise drug delivery and reduced off-target effects.
Data Source
AI summary
The present invention relates to a nitrogen-containing heterocyclic compound and the use thereof. Specifically, provided is a compound of formula I or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof. The compound has excellent and precise therapeutic effects on tumors with low expression or non-expression of the NNMT gene, high expression of DNA methylase, high expression of UHRF1, a high methylation level of nucleotide sites of the NNMT gene, and/or a high methylation level of DNACpG site in a NNMT gene region.